Lord, Abbett & Co. LLC Adma Biologics, Inc. Transaction History

Lord, Abbett & Co. LLC

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 14, 2025	SELL	$17.6 - $24.51 $8.1 Million - $11.3 Million	-460,099 Reduced 20.53%	1,781,524 $32.4 Million
Q1 2025 May 13, 2025	BUY	$15.44 - $20.61 $530,302 - $707,871	34,346 Added 1.56%	2,241,623 $44.5 Million
Q4 2024 Feb 14, 2025	SELL	$15.62 - $22.62 $13.9 Million - $20.1 Million	-887,180 Reduced 28.67%	2,207,277 $37.9 Million
Q3 2024 Nov 14, 2024	BUY	$11.21 - $20.03 $34.7 Million - $62 Million	3,094,457 New	3,094,457 $61.9 Million

401

205M

3.06M

1.88M

Ticker ADMA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 196,356,992
Market Cap $3.06B
Description
ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. It offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primar...

Get notified when there are updates to the investment portfolio of Lord, Abbett & Co. LLC, based on Form 13F filings with the SEC.

Stay updated on Lord, Abbett & Co. LLC with notifications on news.